MTR and myocardial infarction: It might be argued that the use of immunosuppression might have limited the effectiveness of the human monocytes used in this porcine trial, and therefore that using these cells on pure autologous clinical grounds, e.g., autologous hCD16+ Ms being used in MI patients, could lead to larger effect sizes.